CUTANEOUS MEASURES OF DIABETIC NEUROPATHY

糖尿病神经病变的皮肤测量

• 批准号: 7718498
• 负责人: A. Gordon Smith
• 金额: $ 4万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718498
• 关键词: Biopsy; Computer Retrieval of Information on Scientific Projects Database; Cutaneous; Development; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Neuropathies; End Point; Fiber; Functional disorder; Funding; Goals; Grant; Injury; Institution; Kidney Diseases; Measurement; Measures; Nerve Fibers; Neuropathy; Nitric Oxide; Pain; Purpose; Research; Research Personnel; Resources; Retinal Diseases; Risk; Severities; Skin; Source; United States National Institutes of Health; density

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this proposal is to develop, evaluate, and validate surrogate measures of neuropathy progression appropriate to the painful, small fiber neuropathy typical of early diabetes and to investigate the relationship between cutaneous microvascular dysfunction and other microvascular endpoints (retinopathy and nephropathy). We hypothesize that decreased nitric oxide and microvascular injury are important in the initiation of diabetic neuropathy (DN), and abnormal cutaneous microvascular function will precede the development of neuropathy and other microvascular complications. Skin biopsy with measurement of intraepidermal nerve fiber density (IENFD) will be a sensitive marker of subsequent axonal loss and will serve as a useful measure of early DN progression. The project goals are to validate IENFD as a progression measure of mild DN and to correlate cutaneous microvascular dysfunction with severity of small fiber loss and risk of developing microvascular complications.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该提案的目的是开发，评估和验证适用于早期糖尿病典型的疼痛，小纤维神经病的神经病进展的替代措施，并研究皮肤微血管功能障碍与其他微血管终点（视网膜病和肾病）之间的关系。 我们假设减少一氧化氮和微血管损伤在糖尿病神经病（DN）的启动中很重要，皮肤微血管功能异常将在神经病和其他微血管并发症的发展之前。 皮肤活检通过测量表皮内神经纤维密度（IENFD）将是随后的轴突损失的敏感标志物，并将作为早期DN进展的有用度量。 项目目标是验证IENFD作为轻度DN的进展度量，并将皮肤微血管功能障碍与小纤维损失的严重程度和发生微血管并发症的风险相关。